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Background: In patients presenting with peripheral lymphadenopathy, it is critical to effectively identify those with
underlying cancer who require urgent specialist care.
Methods: We analyzed a large dataset of 1000 consecutive patients with unexplained lymphadenopathy referred
between 2001 and 2009 to the Royal Marsden Hospital (RMH) rapid access lymph node diagnostic clinic (LNDC).
Results: Cancer was diagnosed in 14% of patients. Factors predictive for malignant disease were male sex, age,
supraclavicular and multiple site involvement. Cancer-associated symptoms were present for a median of 8 weeks.
The median time from referral to start of cancer therapy was 53 days. Fine needle aspiration (FNA) was performed
in 83% of patients with malignancies. Sensitivity and specificity of FNA were limited (50 and 87%, respectively for
any malignancy; 30 and 79%, respectively for lymphoma). The vast majority of cancer patients received diagnostic
biopsies on the basis of suspicious clinical and ultrasound findings; the FNA result contributed to establishing the
diagnosis in only 4 cases.
Conclusions: In conclusion, we demonstrate that Oncologist-led rapid access clinics are successful concepts to
assess patients with unexplained lymphadenopathy. Our data suggest that a routine use of FNA should be
reconsidered in this setting.
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Peripheral lymphadenopathy has a wide range of infectious,
neoplastic and inflammatory differential diagnoses. When
assessing patients with unexplained lymphadenopathy, the
main challenge is to identify patients with malignancy or
other critical conditions requiring urgent specialist care. In
addition, the diagnostic work-up should minimize unneces-
sary procedures and avoid prolonged hospitalization in the
interest of cost-effectiveness and patients’ satisfaction.
To optimize management of patients with lymphaden-
opathy and suspicion of cancer, rapid access lump clinics* Correspondence: ian.chau@rmh.nhs.uk
1Department of Medicine, Royal Marsden NHS Foundation Trust, Downs
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(http://creativecommons.org/publicdomain/zehave been implemented throughout the UK, allowing
quick referral routes and close collaboration between
hemato-oncologists, radiologists, ENT specialist and sur-
geons [1]. Similarly, quick diagnosis units have been suc-
cessfully introduced in other European countries [2] and
were recently proposed as suitable diagnostic services
for the US healthcare system [3]. However, the optimal
set-up of these clinics remains a matter of debate given the
difficult task of dealing with a magnitude of distinct condi-
tions in an effective way. Data on performance and out-
come of rapid access clinics are therefore essential to
further improve this service and to define the most ad-
equate diagnostic pathways for patients with unexplained
lymphadenopathy.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Table 1 Diagnostic categories
Category no.
Malignant tumor 138
Lymphoma 81
Other hematological malignancy 2
Solid tumor 55
Benign tumor 91
Non-neoplastic, non-infectious lesion 111
Cyst 47
Vascular malformation 3
Hematoma 4
Normal tissue/variant 46
Goiter 4
Hernia 3
Other 4
Infectious/inflammatory disease 89
Reactive/unspecific lymphadenopathy 510
Nothing palpable 61
Diagnostic categories of the total study cohort (n = 1000)
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diagnoses in patients with unclear lymphadenopathy, with
the incidence anticipated to rise in the next decades.
Lymphomas comprise a heterogeneous group of
hematologic malignancies, the most common ones
being diffuse large B cell lymphoma (DLBCL), follicular
lymphoma (FL) and Hodgkin lymphoma (HL). Lymphoma
patients often present with unspecific symptoms com-
monly seen in non-severe illnesses, which can cause sig-
nificant delays to specialist referral [4]. Excision biopsy
remains the gold standard for diagnosing lymphoma and
the full histological work-up requires complex immuno-
histochemical analyses by an experienced histopathologist.
Timely diagnosis and start of treatment is considered par-
ticularly important for DLBCL and HL patients who can
be cured by multi-agent chemotherapies.
We have successfully established a rapid access multi-
disciplinary lymph node diagnostic clinic (LNDC) for
unexplained lymphadenopathy at the Royal Marsden
Hospital (RMH), a tertiary referral comprehensive
cancer centre [5]. Here, we report on the outcome of
1000 consecutive patients referred from 2001 and 2009
to the LNDC with focus on patients diagnosed with
lymphoma.
Methods
We analyzed 1000 consecutive patients referred between
September 2001 and September 2009 to the RMH LNDC
with available data. The analysis was performed as part of a
designated service evaluation for this time period, but re-
sults are representative of the current standard in this
clinic. The LNDC at RMH was established in 1996 as a
rapid access clinic for patients with unexplained lymph-
adenopathy referred by their General Practitioners [5]. The
clinic is held twice a week. The core clinical team com-
prises a consultant medical oncologist and a lymphoma
clinical nurse specialist.
Depending on clinical presentation, diagnostic pro-
cedures were arranged as described before [5], in-
cluding blood tests, microbiology assessments, ultrasound
(US), computed tomography (CT) and fine needle aspir-
ation (FNA). There were designated slots for US assess-
ment and results were immediately available. FNA cytology
results were available within 1 week and graded C0-C5 as
described before [5]. Patients were referred for diagnostic
biopsies if suspicion of malignancy was high.
Patients diagnosed with malignancies or benign tumors
that required surgical intervention were referred internally
to the respective RMH units. Patients with non-malignant
conditions for specific treatment were referred to other
hospitals as appropriate. Patients with benign reactive
lymphadenopathy or self-limiting diseases were discharged
from RMH, either immediately or after follow-up clinic
visits.Clinical data, diagnostic results and details on patient
management were retrospectively collected on the RMH
Electronic Patient Record system. An experienced histo-
pathologist reviewed all lymph node biopsies where a final
diagnosis of lymphoma was made. The date of diagnosis for
malignant disease was defined as the date of final histo-
logical diagnosis. Lymph node areas involved were com-
pared between patient groups using the chi-square test.
Multivariate analysis for prediction of malignancy was per-
formed using a stepwise logistic regression model including
the following variables: age, gender, ethnicity (white vs.
non-white) and site of lymphadenopathy (cervical, axillary,
inguinal, extranodal, multiple sites). Data analysis was per-
formed using stata version 13.1.
Results
Characteristics and diagnoses of study patients
We analyzed 1000 patients referred between 2001 and 2009
to the RMH LNDC. Patients had a median age of 41 years
(range 16–94), were mainly Caucasians (83%) and predom-
inantly female (63%). Malignant disease was diagnosed
in 138 (14%) patients (81 with lymphoma (median age
55 years) and 55 with solid tumors (median age 58 years);
Table 1). Ninety-one patients had benign neoplasms (me-
dian age 50 years) and 89 patients were diagnosed with spe-
cific infectious or inflammatory diseases (median age
37 years). The majority of cases (62%) either had reactive/
unspecific lymphadenopathy (n = 510; median age 37 years),
normal tissue/anatomical variants (e.g. prominent muscle;
n = 46; median age 47 years) or no palpable lesion (n = 61;
median age 46 years; Table 1). The category reactive/
Table 2 Specific diagnoses
Lymphoma subtypes (no.), n = 81
Hodgkin lymphoma (incl. 1 PTLD) 19
Diffuse large B cell lymphoma 16
Mantle cell lymphoma 4
Burkitt lymphoma 1
Follicular lymphoma 31
Small lymphocytic lymphoma 7
Marginal zone lymphoma 1
Lymphoplasmacytic lymphoma 2
Solid tumors (no.), n = 55
Breast 6
Head and neck (SCC) 20
Thyroid 1
Salivary gland 4
Upper GI adenocarcinoma (1 oesophageal, 1 gastric) 2
Cervix/ovarian 2
Skin (8 Melanoma, 1 SCC, 1 Merkel cell) 10
Prostate 1
Lung (non-small cell) 1
Renal 1
Olfactory neuroblastoma 1
Unknown Primary 6
Benign tumors (no.), n = 91
Angioma/angiofibroma 2
Lipoma 44
Fibroadenoma 6
Pilomatrixoma 2
Pleomorphic salivary gland adenoma 15
Warthin’s tumor 18
Granular cell tumor 1
Follicular adenoma (thyroid) 1
Schwannoma 1
Not specified 1
Infectious/inflammatory diseases (no.), n = 89
Chronic sialadenitis/tonsillitis 12
Dermatopathic lymphadenopathy 12
Local inflammation/abscess 8
Sarcoidosis/granuloma 13
Kikuchi’s disease 2
Specific acute infections 42
Toxoplasmosis 14
Tuberculosis 13
Epstein-Barr virus 6
Human immunodeficiency virus 5
Syphilis 1
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lymph nodes. Of 510 patients with reactive/unspecific
lymphadenopathy, 247 (48%) had lymph nodes less than
1 cm in size and 52 (10%) had symptom duration of less
than 6 weeks.
Table 2 shows specific tumor subtypes and infec-
tious/inflammatory diseases diagnosed. Forty-four percent
of lymphomas were potentially curable subtypes (HL,
DLBCL, Burkitt lymphoma). The most common lymph-
oma subtype was FL (n = 31). Among solid tumors, squa-
mous cell carcinomas (SCC) of the head and neck (n = 20)
and metastatic melanoma (n = 8) were most frequently
diagnosed.
Clinical presentation of cancer patients
All patients diagnosed with malignant disease pre-
sented with nodes/lumps of more than 1.5 cm in size.
Cancer-associated symptoms were present for a median of
8 weeks (range 0–832). Of 35 patients with HL or DLBCL,
15 (43%) had elevated LDH levels and 5 (14%) had B-
symptoms as indicators for highly proliferative disease. Me-
dian duration of symptoms in these patients was 7 weeks
(range 1–104).
Patients with malignant disease presented significantly
more often with supraclavicular nodes and lymphadenop-
athy involving multiple sites compared to non-malignant
cases (Table 3). Frequency of extranodal involvement was
significantly lower in malignant vs. non-malignant condi-
tions (P = 0.009). Axillary involvement was more frequently
seen in solid tumors as compared to lymphomas (16% vs.
5%; P = 0.03). Lymphomas presented significantly more
often with multiple site involvement (22% vs. 5%; P = 0.008)
in comparison to solid tumors.
In multivariate analyses, supraclavicular and multiple
site involvement were significantly predictive of malig-
nancy, whereas extranodal involvement was an inde-
pendent predictor of non-malignant disease (Table 4). In
addition, higher age and male sex were predictive of ma-
lignant disease.
Cancer treatment and waiting times
Time to final diagnosis and treatment was assessed in 122
cancer patients with available data. The median time from
first clinic visit to full histological diagnosis was 22 days
(range 1–924), 28 days for lymphomas (range 7–356) and
19 days for solid tumors (range 1–924). The main reason
for diagnostic delays in lymphoma cases was presence of
mild/intermittent symptoms, leading to prolonged moni-
toring of patients before a diagnostic biopsy was arranged.
Seventy-five (56%) patients with malignant disease re-
ceived systemic treatment, 19 (14%) received initial radio-
therapy and 20 (15%) primary surgery. Four patients with
metastatic solid tumors received best supportive care only.
In 16 patients diagnosed with indolent lymphoma a watch
Table 2 Specific diagnoses (Continued)
Lymphoma subtypes (no.), n = 81
Mumps 1
Bartonella infection 2
PTLD indicates post -transplant lymphoproliferative disorder; SCC indicates
squamous cell carcinoma
Specific diagnoses assigned to patients on the study (n = 1000)
Kühnl et al. BMC Hematology  (2018) 18:19 Page 4 of 7and wait policy was adopted. The median time from refer-
ral to start of therapy was 53 days (range 21–930; 56 days
for lymphomas and 50 days for solid tumors), including
watch and wait and best supportive care as therapies.
After exclusion of cases delayed due to patients’ decision,
the median times to therapy were 50 days (lymphomas)
and 48 days (solid tumors).
Rapid and streamline pathways for diagnosis and ther-
apy might be of particular importance for potentially
curable lymphomas, such as HL and DLBCL. Median
time from referral to start of therapy in HL was 48 days
(range 26–202) and 45 days for DLBCL (range 22–116).
Median time from referral to start of therapy has im-
proved since implementing specific cancer waiting time
targets in the UK in 2005, with a median time of 38 days
between 2005 and 2009 compared to 51 days between
2001 and 2004 (Additional file 1: Figure S1).
Diagnostic procedures
96% of patients with malignancy and all lymphoma pa-
tients had a core or excision biopsy as diagnostic pro-
cedure. Six solid tumor cases were diagnosed with FNA
only (5 did not have a biopsy, 1 had a non-diagnostic bi-
opsy). FNA was performed in 423 of 1000 cases, in 114/
138 (83%) of malignancies and in 63/81 (78%) of
lymphomas.
FNA results were inadequate (C0/C1) in 94/423 (22%)
of patients, which was similar with US guidance [68/316
(22%)] and without [26/107 (24%)]. FNA raised suspicion
of cancer (C3–5 cytology) in 57/114 (50%) of all malignan-
cies and in 19/81 (24%) of lymphomas. Benign cytology
(C2) was seen in 44/114 (39%) malignancies, the majority
of which were lymphomas (n = 39). Sensitivity of US and
FNA was 93 and 50% to detect any malignancy, and 88
and 30% to detect lymphoma, respectively. Specificity wasTable 3 Anatomical areas involved
Areas involved Malignant (n = 138) no. (%)
Cervical 71 (51)
Supraclavicular 11 (8)
Axillary 13 (9)
Inguinal 19 (14)
Multiple sites 21 (15)
Extranodal 3 (2)
Sites of nodal- and extranodal involvement in malignant and non-malignant cases96% (US) and 87% (FNA) for detection of all malignancies,
and 91% (US) and 79% (FNA) for detection of lymphoma.
Given the limited sensitivity and specificity of FNA as
diagnostic tool, we analyzed which diagnostic finding ac-
tually prompted the LNDC team to arrange a biopsy in
malignant cases (n = 133; Table 5). Most patients (n = 129)
were referred to biopsy on the basis of high clinical suspi-
cion with or without additional abnormal findings in US
performed on the day of clinic visit. Only in 2 cases with
cancer of unknown primary and 1 Burkitt lymphoma pa-
tient, the FNA C5 result led to referral for biopsy. In 1 pa-
tient with lymphoplasmacytic lymphoma, the FNA result
(C3) was the only finding that raised suspicion of malig-
nancy and prompted a diagnostic biopsy. In 10 patients
with solid tumors (5 head and neck, 3 breast, 1 salivary
gland, 1 unknown primary), the FNA C4/5 result was im-
portant to decide on doing a core rather than excision bi-
opsy. In 11 patients with minor symptoms (10 lymphoma
cases and 1 salivary gland carcinoma), the diagnostic bi-
opsy was delayed due to FNA C2 results, with a median
time from first visit to diagnosis of 79 days (range 47–
212). Thus, FNA was of limited value for establishing the
diagnosis in the majority of malignant diseases in our
series.
Most non-malignant cases [539/862 (63%)] did not
have either biopsy or FNA. Among 310 non-malignant
cases undergoing FNA, 81 (26%) were inadequate, 190
(61%) showed benign cytology and 13 (4%) raised suspi-
cion of malignancy. In 26 cases the FNA result was diag-
nostic for the non-malignant condition (11 pleomorphic
salivary gland adenomas, 6 Warthin’s tumors, 3 bran-
chial cysts, 2 tuberculosis cases, 1 abscess, 1 toxoplas-
mosis, 1 hematoma, 1 pilomatrixoma). Biopsies were not
performed in 742/862 (86%) of non-malignant cases,
mainly guided by clinical examination and US (Add-
itional file 1: Figure S2). In 152/742 (20%) cases with
non-malignant disease, the FNA result helped to estab-
lish the diagnosis and to avoid a more invasive biopsy.
Discussion
Implementation of rapid access diagnostic clinics for pa-
tients with unexplained lymphadenopathy facilitates early
diagnosis of cancer. Here, we provide a detailed report onNon-malignant (n = 862) no. (%) P
518 (60) 0.055
26 (3) 0.004
119 (14) 0.158
77 (9) 0.073
47 (5) < 0.001
75 (9) 0.008
Table 4 Multivariable analysis for prediction of malignant
disease (n = 1000)
Variables OR 95% CI P
Age (years) 1.04 1.03–1.06 < 0.001
Male sex 2.84 1.92–4.21 < 0.001
Supraclavicular 2.41 1.10–5.31 0.03
Multiple sites 4.02 2.20–7.34 < 0.001
Extranodal 0.17 0.05–0.58 0.004
OR indicates odds ratio, CI indicates confidence interval
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LNDC at RMH between 2001 and 2009.
The pick-up rate for malignant diseases in our study was
14% which is in line with previous findings at our [5] and
other institutions [6] and similar to results from neck lump
clinics [7–10]. However, a recent Spanish study investigat-
ing 372 patients with unexplained lymphadenopathy re-
ferred from primary health care centers to an internist-led
quick diagnosis unit reported a cancer rate of 32% [2]. The
study excluded patients without palpable lesion at the time
of clinic visit, which was found in 6% of our cases. In
addition, they had a lower incidence of reactive nodes
(42%) and only 4 cases with benign tumors. In contrast, re-
active and benign findings accounted for 71% of referrals in
our series. Given the set-up of our clinic in a tertiary care
cancer center involving assessment by a consultant medical
oncologist and a lymphoma clinical nurse specialist, a bet-
ter selection of patients who require urgent assessment
would be preferable.
Most cancer referral guidelines suggest referral of pa-
tients with unclear lymphadenopathy or lumps greater than
1-2 cm in size [1, 11]. Our findings support adherence to a
minimum size limit. Half of reactive nodes but no case ofTable 5 Indication for biopsy in malignant cases (n = 133)
Indication for biopsy in
malignant cases
Reason for US/FNA not impacting on
decision-making
Clinical suspicion (n = 68) No US performed (n = 63)
US inconclusive/not suspicious (n = 5)
No FNA performed (n = 19)
FNA results inconclusive/not suspicious/
not awaited (n = 49)
Clinical and US suspicion (n
= 61)
No FNA performed (n = 5)
FNA results inconclusive/not suspicious/
not awaited (n = 56)
Clinical suspicion and FNA
C5 (n = 2)
No US performed (n = 2)
FNA C3 result (n = 1)a No US performed (n = 1)
Clinical and US suspicion,
FNA C5 (n = 1)
Not applicable
aNo clinical suspicion of malignancy
Diagnostic findings that led to performing a confirmatory biopsy in patients
with malignant disease (n = 133)malignancy presented with sub-centimeter lymphadenop-
athy in our cohort. The use of calipers for exact nodal mea-
surements might help to increase the quality of referrals. In
addition, extranodal lumps (not in the breast or head and
neck) that are unchanged in size for many years should not
be subject to an urgent referral pathway.
Our study shows that by far the most important diagnos-
tic tool is examination/evaluation by an experienced clin-
ician, taking into account several factors to estimate the
probability of malignancy, such as size, texture and site of
the lump, symptoms, risk factors, and examination of
loco-regional and disease-related sites. The majority of
non-malignant cases did not undergo any invasive investi-
gation and could therefore efficiently be assessed outside a
specialist center. Thus, some form of local Hemato-
oncology involvement or remote Specialist triaging,
alongside improved communication and guidance be-
tween primary care and specialist centers might further
assist appropriate patient selection. This would allow for a
more effective use of resources and would spare low-risk
patients the psychological burden of being assessed for
cancer.
We and others have identified clinical factors in patients
with unexplained lymphadenopathy that predict for malig-
nancy [5, 6] Here, we validate our previous findings identi-
fying male sex, age, as well as supraclavicular and multiple
site involvement as independently predictive for malignant
disease. Presence of these features in patients with unex-
plained lymphadenopathy should alert clinicians to the pos-
sibility of underlying cancer.
Referrals of patients with lymphomas and solid tumors
occurred in a timely manner with median symptom dur-
ation of only 8 weeks at the time of presentation in our
clinic. Particularly lymphoma-related symptoms are often
not indicative of malignant disease or serious illness, which
usually leads to a longer time to seeking medical help com-
pared to other cancers [4]. Howell et al. [12] reported a me-
dian time of 10 weeks from onset of lymphoma-related
symptoms to seeking medical help and Summerfield et al.
[13] observed a mean time of 16 weeks. The shorter inter-
vals in our series might indicate an increasing public aware-
ness about the need to investigate an unexplained change
in health. Referred patients were seen promptly in our
clinic (mean waiting time of 7 days). A median time from
referral to start of treatment of 53 days in patients diag-
nosed with cancer still warrants improvement. Similar to
previous findings [12], main delays occurred after the first
clinic appointment, and were predominantly “diagnostic
delays” for lymphoma patients (mainly indolent lymph-
omas) and “therapy delays” in solid tumors (mainly pallia-
tive treatment).
Indolent lymphomas typically present with diffuse, mild
symptoms and have a high false-negative rate in FNA as-
sessment. Accordingly, the main reason for delay in the
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tional approach, in some cases supported by benign FNA
results. To diagnose indolent lymphomas quicker, cases
without high clinical suspicion of malignancy would gener-
ally have to undergo early biopsies. This would significantly
increase the rate of invasive procedures for non-cancer
patients.
FNA assessment on the day of clinic visit in patients with
suspicion of malignancy is part of our LNDC set-up. This is
in line with national recommendations for rapid access
head and neck lump clinics. However, lymphomas are usu-
ally the most common malignancies diagnosed in clinics
for general lymphadenopathy or head and neck lumps and
FNA is not regarded an appropriate tool for lymphoma
diagnosis. Limitations of FNA in lymphoma are well docu-
mented [14–16]. Our findings further support these data
with the sensitivity of FNA being only 30%. Accuracy of
FNA is better for solid tumors, but significantly depends on
the exact site of disease as shown for head and neck lumps
[16]. A rapid access LNDC deals with a variety of cancer
types and routine use of FNA for every patient might not
be optimal in this regard.
FNA as primary diagnostic tool should have a minimal
rate of inadequate and false-negative samples and should
decrease the need for diagnostic biopsies. This however
highly depends on the clinic setting: local FNA perform-
ance, clinical expertise, availability/quality of US assessment
and frequency of cancer types. The utility of FNA is cer-
tainly higher in cytologist-led one-stop clinics were samples
can be immediately assessed and retaken if necessary. In
addition, accuracy of FNA for lymphoma, particularly high-
grade NHL, can be improved by flow cytometry [17, 18],
but this is an expensive technique only available at special-
ist centers. Of note, even if FNA is indicative/diagnostic for
lymphoma, this will not substitute for a surgical biopsy to
allow the full range of tests needed for exact diagnosis. Also
in solid tumors, the majority of patients still require a bi-
opsy after FNA to establish the diagnosis and to provide
sufficient material for molecular and immunohistochemical
testings. In view of the increasing use of targeted therapies,
the need for adequate tissue to assess predictive biomarkers
will further grow. In our series, only 5 patients with solid
tumors were diagnosed with FNA only. In a further few
cancer cases, FNA results were important to decide on per-
forming a biopsy. In the majority of malignant cases, indi-
cation for biopsy was guided by clinical suspicion and US
features. In addition, many patients required repeat aspira-
tions (data not shown), which involves additional costs and
follow-up visits. Repeat false-negative results (including in-
adequate samples) are not only misleading for clinicians,
but also impose significant stress on patients.
US is highly sensitive to distinguish malignant from
non-malignant lumps and can provide important infor-
mation about the type of malignancy. US is cheap, safeand widely available. Our data indicate that if an inte-
grated US service and a highly experienced clinical team
is available, pre-selection of patients for FNA should be
more stringent. For example, FNA should be performed
if there is high suspicion of SCC of the head and neck.
Or, if there is low suspicion of malignancy and a benign
FNA result is regarded sufficient to rule out malignancy.
On the other hand, FNA should be avoided if lymphoma
is suspected (e.g. age, B-symptoms, typical US features).
Conclusions
In conclusion, this is the largest dataset of a rapid access
clinic for patients with unclear lymphadenopathy. Our
results provide valuable insights into the successful per-
formance of our LNDC and build a basis for further im-
provement of this diagnostic service model.
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